Financial Performance - In Q1 2025, the company achieved a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [2] - The net profit attributable to shareholders was 1.935 billion CNY, up 13.67% year-on-year [2] - The basic earnings per share reached 1.08 CNY, reflecting a growth of 13.66% [2] - The net cash flow from operating activities was 714 million CNY, showing a significant increase of 35.39% [2] - The weighted average return on equity was 4.86%, an increase of 0.68 percentage points year-on-year [2] - The company had cash and cash equivalents of 11.062 billion CNY and total assets of 54.253 billion CNY [2] Pharmaceutical Business Group - In 2024, the pharmaceutical business group reported a main business revenue of 6.924 billion CNY, a year-on-year growth of 11.8% [3] - The sales revenue of the core product, Yunnan Baiyao aerosol, exceeded 2.1 billion CNY, with a growth rate of over 26% [3] - Other significant products, such as Yunnan Baiyao plaster and capsules, also saw substantial revenue growth [4] - The sales revenue of Pudilan anti-inflammatory tablets reached nearly 200 million CNY, with a year-on-year increase of over 22% [4] Health Products Business Group - The health products business group aims to establish itself as a benchmark for new concepts in Chinese health living [5] - The group plans to enhance its oral care business while expanding into professional markets and hotel services [5] - There is a focus on increasing the scale of hair care products and expanding into skin management [5] Distribution Channels - The health products segment has a well-established national sales team, maintaining a leading market share in oral care products [6] - The company is optimizing its distribution channels, strengthening traditional offline advantages while exploring new retail formats [6] - This channel strategy significantly enhances the company's market competitiveness and supports new product commercialization [7] Dividend Distribution - For the 2024 fiscal year, the company plans to distribute a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.164 billion CNY [8] - The total cash dividend for 2024, including a special dividend, amounts to 23.98 CNY per 10 shares, totaling approximately 4.279 billion CNY, which represents 90.09% of the net profit attributable to shareholders [8]

Financial Performance - In Q1 2025, the company achieved a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [2] - The net profit attributable to shareholders was 1.935 billion CNY, up 13.67% year-on-year [2] - The basic earnings per share reached 1.08 CNY, reflecting a growth of 13.66% [2] - The net cash flow from operating activities was 714 million CNY, an increase of 35.39% [2] - The weighted average return on equity was 4.86%, up by 0.68 percentage points year-on-year [2] - The company held cash and cash equivalents of 11.062 billion CNY, with total assets amounting to 54.253 billion CNY [2] R&D Advantages - Strong R&D capabilities with a rich reserve of leading talents, established a joint research center with Peking University [3][4] - Integrated R&D resources across multiple cities, enhancing collaboration with top research institutions [4] - Proactive strategic layout in nuclear medicine, focusing on unmet clinical needs in oncology and immunology [4] - Financial strength to support long-term R&D investments in nuclear medicine [4] Traditional Chinese Medicine (TCM) Supply Chain Development - The company is taking the lead in the TCM supply chain in Yunnan, focusing on seed industry, planting, processing, marketing, and branding [5][6] - Established a specialized company for TCM seed industry, with 4,593 acres of GAP varieties reported in 2024 [6] - Significant growth in production, with a 180% increase in fresh processing and 182% in food and health products [6] - Launched the 'Smart Cloud Medicine' platform, facilitating over 100 million CNY in transactions [6] - Participated in the revision of standards for TCM in the 2025 edition of the Chinese Pharmacopoeia [6] Pharmaceutical Business Growth - The pharmaceutical division focused on comprehensive pain management, enhancing brand recognition in the field [7][8] - Continued clinical research on core products, expanding applications in various medical scenarios [8] - Successful marketing initiatives aimed at younger demographics, leading to increased sales [8] - Established efficient online business processes to enhance operational effectiveness [8]

Group 1: Financial Performance - In Q1 2025, the company achieved a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [2] - The net profit attributable to shareholders was 1.935 billion CNY, up 13.67% year-on-year [2] - The basic earnings per share reached 1.08 CNY, reflecting a 13.66% increase compared to the previous year [2] - The net cash flow from operating activities was 714 million CNY, showing a significant growth of 35.39% [2] - The weighted average return on equity was 4.86%, an increase of 0.68 percentage points year-on-year [2] - The company had a cash balance of 11.062 billion CNY and total assets of 54.253 billion CNY [2] Group 2: Pharmaceutical Business Performance - The pharmaceutical segment focused on pain management, enhancing brand recognition and product ecosystem [4] - Clinical research in areas such as diabetic foot and skeletal pain showed steady progress, expanding product application scenarios [4] - Successful marketing initiatives, including the 'Walk and Play' campaign, contributed to brand youthfulness and increased product penetration [4] - The company established an efficient operational system to enhance production and marketing effectiveness [4] Group 3: Traditional Chinese Medicine (TCM) Supply Chain Development - The company is committed to leading the TCM supply chain in Yunnan, focusing on seed industry, cultivation, processing, and branding [6] - A new company was established for TCM seed industry, providing control over genetic resources [6] - The processing platform saw a production increase of 180% for medicinal materials and 182% for health products [6] - The 'Smart Cloud Medicine' platform was launched, facilitating transactions exceeding 100 million CNY [6] - The company participated in the revision of standards for TCM products, leading in the development of processing standards [6] Group 4: Nuclear Medicine Research Progress - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024, with positive stability and safety results reported [8] - The company’s subsidiary received approval for clinical trials of INR102, an innovative radioactive treatment for prostate cancer [8]

Financial Performance - In Q1 2025, the company achieved a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [2] - The net profit attributable to shareholders was 1.935 billion CNY, up 13.67% year-on-year [2] - The basic earnings per share reached 1.08 CNY, reflecting a 13.66% increase [2] - The net cash flow from operating activities was 714 million CNY, showing a significant growth of 35.39% [2] - The weighted average return on equity was 4.86%, an increase of 0.68 percentage points year-on-year [2] - The company held cash and cash equivalents of 11.062 billion CNY, with total assets amounting to 54.253 billion CNY [2] Pharmaceutical Business Growth - The pharmaceutical segment focused on "comprehensive management of pain in the injury field" as a strategic direction [3] - The segment enhanced its core products' efficacy in pain management through academic clinical research [4] - Key areas of focus included cardiovascular, respiratory, and pediatric medicine, with ongoing efforts to enrich the product pipeline [4] - Marketing strategies included the successful cultivation of proprietary sports IP, which contributed to brand youthfulness and increased product penetration [4] Oral Care Product Performance - In 2024, Yunnan Baiyao toothpaste maintained the top market share in the domestic oral care sector [5] - During major sales events like "618" and "Double Eleven," the brand consistently ranked first in online oral care sales [5] - Content marketing initiatives, such as the "Healthy Oral 123 Plan," significantly enhanced brand visibility, achieving over 6.43 billion exposures [6] Dividend Distribution - For the 2024 fiscal year, the company announced a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.164 billion CNY [7] - The total cash dividend for 2024, including special dividends, amounted to 23.98 CNY per 10 shares, representing 90.09% of the net profit attributable to shareholders [7] Nuclear Medicine R&D Progress - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024, with promising stability and safety results reported in November [9] - The company’s subsidiary received approval for clinical trials of INR102, an innovative drug for treating metastatic castration-resistant prostate cancer [9]

Financial Performance - In Q1 2025, the company achieved a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [2] - The net profit attributable to shareholders was 1.935 billion CNY, up 13.67% year-on-year [2] - The basic earnings per share reached 1.08 CNY, reflecting a growth of 13.66% [2] - The net cash flow from operating activities was 714 million CNY, an increase of 35.39% [2] - The weighted average return on equity was 4.86%, up by 0.68 percentage points year-on-year [2] - The company had a cash balance of 11.062 billion CNY and total assets of 54.253 billion CNY [2] Pharmaceutical Business Development - The pharmaceutical segment focused on establishing itself as the leading brand in pain management, launching a new pain management model [3] - Key areas of focus included cardiovascular, respiratory, and pediatric medicine, enhancing the product pipeline [4] - Clinical research in diabetes foot, skeletal pain, and other areas showed steady progress, expanding product application scenarios [4] - Marketing efforts included the successful promotion of the proprietary sports IP "Let's Go Play Ball," enhancing brand youthfulness [4] - The company optimized its operational platform, achieving significant quality and efficiency improvements throughout the year [4] Health Products Channel Development - The company has a well-established national sales team for health products, maintaining a leading market share in toothpaste [5] - Continuous optimization of the entire channel has strengthened traditional offline advantages while exploring new retail formats [6] - The channel advantages have significantly enhanced market competitiveness and laid a foundation for new product commercialization [6] Future Development Strategy - The company aims for growth through both "internal" and "external" collaborative development, optimizing its industrial portfolio [7] - "Internal" development focuses on enhancing efficiency and stability across the pharmaceutical, health, and distribution sectors [7] - "External" development involves strategic mergers and collaborations to overcome growth bottlenecks and build a sustainable industrial system [7] Dividend Distribution - For the 2024 fiscal year, the company plans to distribute a cash dividend of 11.85 CNY per 10 shares, with no stock dividends [8] - A special dividend of 12.13 CNY per 10 shares was completed in November 2024, totaling 2.164 billion CNY [8] - The total cash dividend for 2024 amounts to 23.98 CNY per 10 shares, totaling 4.279 billion CNY, which is 90.09% of the net profit attributable to shareholders [9]

Group 1: Pharmaceutical Business Growth - The pharmaceutical segment aims for significant growth in 2024 by focusing on becoming the leading brand in pain management, enhancing product efficacy, and expanding its ecosystem [2] - Clinical research on core products like Yunnan Baiyao (powder) and capsules for diabetic foot and skeletal pain has shown steady progress, opening broader application scenarios [4] - Marketing strategies, including the successful promotion of the self-owned sports IP "Let's Go Play Ball," have improved brand youthfulness and product penetration [4] Group 2: Health Products Channel Development - The company maintains a comprehensive national sales team for health products, with Yunnan Baiyao toothpaste leading the market share in the oral care category [5] - Continuous optimization of the entire channel has strengthened traditional offline advantages while exploring new retail formats, enhancing market competitiveness [5] Group 3: Provincial Pharmaceutical Company Performance - In 2024, the Provincial Pharmaceutical Company achieved a main business revenue of CNY 24.607 billion, a year-on-year increase of 0.48% [6] - Non-pharmaceutical business areas like medical devices and special medical foods saw a sales growth of 14% [7] - The OTC segment experienced an 18% sales increase, while the new specialty pharmacy model grew by 29% [7] Group 4: Future Investment and Acquisition Plans - The company plans to optimize its industrial portfolio through both "internal" and "external" collaborative development, focusing on strategic mergers and partnerships to overcome growth bottlenecks [8]

Financial Performance - In 2024, the company achieved operating revenue of 40.033 billion CNY, a year-on-year increase of 2.36% [2] - Net profit attributable to shareholders reached 4.749 billion CNY, up 16.02% from 4.094 billion CNY in the previous year [2] - Non-recurring net profit attributable to shareholders was 4.523 billion CNY, a 20.18% increase from 3.764 billion CNY [2] - Operating cash flow net amount was 4.297 billion CNY, growing by 22.68% [3] - The weighted average return on net assets was 11.99%, an increase of 1.48 percentage points [3] - Basic earnings per share rose to 2.66 CNY, a 16.16% increase [3] Business Structure and Efficiency - Industrial revenue accounted for 36.14% of total operating revenue, with an industrial revenue growth rate of 5.30% [3] - Industrial gross margin improved to 65.93%, up 1.69 percentage points [3] - Sales expenses decreased by 2.26% year-on-year, while management expenses fell by 1.98% [3] Pharmaceutical Business Performance - The pharmaceutical business group reported main business revenue of 6.924 billion CNY, a year-on-year increase of 11.8% [4] - Sales revenue of Yunnan Baiyao aerosol exceeded 2.1 billion CNY, growing over 26% [4] - Other traditional Chinese medicine products also saw significant growth, with Pudilan's sales nearing 200 million CNY, up over 22% [4] Traditional Chinese Medicine Industry Development - The company is leading the development of Yunnan's traditional Chinese medicine industry, focusing on seed industry, planting, processing, and branding [5][6] - Established Yunnan Baiyao Group Seed Technology Co., Ltd. for seed quality control [6] - The processing platform in Lijiang achieved a production increase of 180% [6] - The "Smart Cloud Medicine" platform launched, facilitating over 100 million CNY in transactions [6] Provincial Pharmaceutical Company Performance - The provincial pharmaceutical company achieved main business revenue of 24.607 billion CNY, a year-on-year increase of 0.48% [7] - Non-drug business sectors like medical devices and special medical foods saw a sales increase of 14% [8] - The OTC sector experienced a sales growth of 18%, while new specialty drug pharmacies grew by 29% [8]

Financial Performance - In 2024, the company achieved a revenue of 40.033 billion CNY, a year-on-year increase of 2.36% [2] - The net profit attributable to shareholders reached 4.749 billion CNY, up 16.02% from 4.094 billion CNY in the previous year [2] - The non-recurring net profit attributable to shareholders was 4.523 billion CNY, reflecting a 20.18% increase from 3.764 billion CNY [2] - Operating cash flow net amount was 4.297 billion CNY, a growth of 22.68% year-on-year [3] - The weighted average return on equity was 11.99%, an increase of 1.48 percentage points [3] - Basic earnings per share were 2.66 CNY, up 16.16% from the previous year [3] Business Structure and Efficiency - The industrial revenue accounted for 36.14% of total revenue, with an industrial revenue growth rate of 5.30% [3] - The industrial gross profit margin was 65.93%, an increase of 1.69 percentage points [3] - Sales expenses decreased by 2.26% and management expenses decreased by 1.98% compared to the previous year [4] - Total assets at the end of the reporting period were 52.914 billion CNY, with net assets attributable to shareholders at 38.832 billion CNY and a debt-to-asset ratio of 26.55% [4] Pharmaceutical Business Performance - The pharmaceutical business group generated a revenue of 6.924 billion CNY, a year-on-year increase of 11.8% [5] - The sales revenue of the core product, Yunnan Baiyao aerosol, exceeded 2.1 billion CNY, with a growth rate of over 26% [5] - Other traditional Chinese medicine products also saw significant growth, with Pudilan's sales nearing 200 million CNY, up over 22% [5] Health Products Performance - The health products business group achieved a revenue of 6.526 billion CNY, a growth of 1.6% [6] - Profit from health products reached 2.191 billion CNY, an increase of 8.36% [6] - Yunnan Baiyao toothpaste maintained the top market share in the domestic oral care sector [6] Dividend Distribution - The company proposed a cash dividend of 11.85 CNY per 10 shares, with a total cash dividend amounting to approximately 2.164 billion CNY [8] - The total cash dividend for 2024, including a special dividend, amounts to 23.98 CNY per 10 shares, totaling approximately 4.279 billion CNY, which represents 90.09% of the net profit attributable to shareholders [8]